Iovance lifts 2026 revenue guidance on Amtagvi demand
Alpha Vantage · Simply Wall Street · · AI-summarised by FinFlash
Iovance Biotherapeutics raised its full-year 2026 revenue guidance to $410-$420 million, citing strong U.S. demand for Amtagvi and Proleukin. The company also appointed Noah Berkowitz as Chief Medical Officer, a hire expected to help advance its cell therapy portfolio. Investors now focus on execution of the updated guidance and its implications for long-term growth and diversification.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.